BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 28230921)

  • 1. Prevalence of promoter mutations in the TERT gene in oral cavity squamous cell carcinoma.
    Chang KP; Wang CI; Pickering CR; Huang Y; Tsai CN; Tsang NM; Kao HK; Cheng MH; Myers JN
    Head Neck; 2017 Jun; 39(6):1131-1137. PubMed ID: 28230921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter hot spot mutations are frequent in Indian cervical and oral squamous cell carcinomas.
    Vinothkumar V; Arunkumar G; Revathidevi S; Arun K; Manikandan M; Rao AK; Rajkumar KS; Ajay C; Rajaraman R; Ramani R; Murugan AK; Munirajan AK
    Tumour Biol; 2016 Jun; 37(6):7907-13. PubMed ID: 26700669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. TERT promoter hotspot mutations and their relationship with TERT levels and telomere erosion in patients with head and neck squamous cell carcinoma.
    Boscolo-Rizzo P; Giunco S; Rampazzo E; Brutti M; Spinato G; Menegaldo A; Stellin M; Mantovani M; Bandolin L; Rossi M; Del Mistro A; Tirelli G; Dei Tos AP; Guerriero A; Niero M; Da Mosto MC; Polesel J; De Rossi A
    J Cancer Res Clin Oncol; 2020 Feb; 146(2):381-389. PubMed ID: 31960186
    [TBL] [Abstract][Full Text] [Related]  

  • 4.
    Yu Y; Fan D; Song X; Zakeri K; Chen L; Kang J; McBride S; Tsai CJ; Dunn L; Sherman E; Katabi N; Dogan S; Cracchiolo J; Cohen M; Boyle JO; Lee M; Valero C; Wang J; Wong R; Morris L; Riaz N; Lee N
    JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34381934
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Telomerase reverse transcriptase (TERT) promoter mutations are rare in urachal cancer.
    Thiem S; Herold T; Krafft U; Bremmer F; Tolkach Y; Szász AM; Kriegsmann J; Gaisa NT; Niedworok C; Szarvas T; Reis H
    Pathol Int; 2017 Dec; 67(12):597-601. PubMed ID: 29047227
    [TBL] [Abstract][Full Text] [Related]  

  • 6. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA.
    Wang N; Liu T; Sofiadis A; Juhlin CC; Zedenius J; Höög A; Larsson C; Xu D
    Cancer; 2014 Oct; 120(19):2965-79. PubMed ID: 24898513
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors.
    Liu T; Brown TC; Juhlin CC; Andreasson A; Wang N; Bäckdahl M; Healy JM; Prasad ML; Korah R; Carling T; Xu D; Larsson C
    Endocr Relat Cancer; 2014 Jun; 21(3):427-34. PubMed ID: 24803525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct profiles of TERT promoter mutations and telomerase expression in head and neck cancer and cervical carcinoma.
    Annunziata C; Pezzuto F; Greggi S; Ionna F; Losito S; Botti G; Buonaguro L; Buonaguro FM; Tornesello ML
    Int J Cancer; 2018 Sep; 143(5):1153-1161. PubMed ID: 29603728
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Frequent TERT Promoter Mutations in Ocular Surface Squamous Neoplasia.
    Scholz SL; Thomasen H; Reis H; Möller I; Darawsha R; Müller B; Dekowski D; Sucker A; Schilling B; Schadendorf D; Steuhl KP; Paschen A; Westekemper H; Meller D; Griewank KG
    Invest Ophthalmol Vis Sci; 2015 Sep; 56(10):5854-61. PubMed ID: 26348634
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas.
    Liu T; Wang N; Cao J; Sofiadis A; Dinets A; Zedenius J; Larsson C; Xu D
    Oncogene; 2014 Oct; 33(42):4978-84. PubMed ID: 24141777
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TERT promoter mutation in adult granulosa cell tumor of the ovary.
    Pilsworth JA; Cochrane DR; Xia Z; Aubert G; Färkkilä AEM; Horlings HM; Yanagida S; Yang W; Lim JLP; Wang YK; Bashashati A; Keul J; Wong A; Norris K; Brucker SY; Taran FA; Krämer B; Staebler A; van Meurs H; Oliva E; Shah SP; Kommoss S; Kommoss F; Gilks CB; Baird DM; Huntsman DG
    Mod Pathol; 2018 Jul; 31(7):1107-1115. PubMed ID: 29449679
    [TBL] [Abstract][Full Text] [Related]  

  • 12. TERT promoter mutations and long telomere length predict poor survival and radiotherapy resistance in gliomas.
    Gao K; Li G; Qu Y; Wang M; Cui B; Ji M; Shi B; Hou P
    Oncotarget; 2016 Feb; 7(8):8712-25. PubMed ID: 26556853
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations.
    Cevik D; Yildiz G; Ozturk M
    World J Gastroenterol; 2015 Jan; 21(1):311-7. PubMed ID: 25574106
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TERT promoter mutations in penile squamous cell carcinoma: high frequency in non-HPV-related type and association with favorable clinicopathologic features.
    Kim SK; Kim JH; Han JH; Cho NH; Kim SJ; Kim SI; Choo SH; Kim JS; Park B; Kwon JE
    J Cancer Res Clin Oncol; 2021 Apr; 147(4):1125-1135. PubMed ID: 33635430
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Arantes LMRB; Cruvinel-Carloni A; de Carvalho AC; Sorroche BP; Carvalho AL; Scapulatempo-Neto C; Reis RM
    Front Oncol; 2020; 10():1275. PubMed ID: 32850388
    [No Abstract]   [Full Text] [Related]  

  • 16. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia.
    Papathomas TG; Oudijk L; Zwarthoff EC; Post E; Duijkers FA; van Noesel MM; Hofland LJ; Pollard PJ; Maher ER; Restuccia DF; Feelders RA; Franssen GJ; Timmers HJ; Sleijfer S; de Herder WW; de Krijger RR; Dinjens WN; Korpershoek E
    Endocr Relat Cancer; 2014 Aug; 21(4):653-61. PubMed ID: 24951106
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome.
    Allory Y; Beukers W; Sagrera A; Flández M; Marqués M; Márquez M; van der Keur KA; Dyrskjot L; Lurkin I; Vermeij M; Carrato A; Lloreta J; Lorente JA; Carrillo-de Santa Pau E; Masius RG; Kogevinas M; Steyerberg EW; van Tilborg AA; Abas C; Orntoft TF; Zuiverloon TC; Malats N; Zwarthoff EC; Real FX
    Eur Urol; 2014 Feb; 65(2):360-6. PubMed ID: 24018021
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of heterozygosity in mammary serine protease inhibitor (maspin) and p53 at chromosome 17 and 18 in oral cavity squamous cell carcinoma.
    Choi KY; Choi HJ; Chung EJ; Lee DJ; Kim JH; Rho YS
    Head Neck; 2015 Sep; 37(9):1239-45. PubMed ID: 24801268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent TERT promoter mutations identified in a large-scale study of multiple tumour types are associated with increased TERT expression and telomerase activation.
    Huang DS; Wang Z; He XJ; Diplas BH; Yang R; Killela PJ; Meng Q; Ye ZY; Wang W; Jiang XT; Xu L; He XL; Zhao ZS; Xu WJ; Wang HJ; Ma YY; Xia YJ; Li L; Zhang RX; Jin T; Zhao ZK; Xu J; Yu S; Wu F; Liang J; Wang S; Jiao Y; Yan H; Tao HQ
    Eur J Cancer; 2015 May; 51(8):969-76. PubMed ID: 25843513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulatory Single Nucleotide Polymorphism Increases TERT Promoter Activity in Thyroid Carcinoma Cells.
    Hirokawa T; Arimasu Y; Chiba T; Nakazato Y; Fujiwara M; Kamma H
    Pathobiology; 2020; 87(6):338-344. PubMed ID: 33227798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.